Australia markets closed

Cyclo Therapeutics, Inc. (CYTH)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4199+0.0199 (+1.42%)
As of 09:51AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 39.63M
Enterprise value 31.41M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)20.94
Price/book (mrq)8.33
Enterprise value/revenue 29.18
Enterprise value/EBITDA -1.57

Trading information

Stock price history

Beta (5Y monthly) -0.14
52-week change 370.73%
S&P500 52-week change 329.57%
52-week high 32.5700
52-week low 30.6700
50-day moving average 31.6694
200-day moving average 31.5182

Share statistics

Avg vol (3-month) 3102.61k
Avg vol (10-day) 3119.75k
Shares outstanding 528.72M
Implied shares outstanding 629.33M
Float 815.87M
% held by insiders 141.27%
% held by institutions 19.76%
Shares short (15 Mar 2024) 4112.59k
Short ratio (15 Mar 2024) 40.85
Short % of float (15 Mar 2024) 40.45%
Short % of shares outstanding (15 Mar 2024) 40.39%
Shares short (prior month 15 Feb 2024) 483.33k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 309 Dec 2020
Ex-dividend date 4N/A
Last split factor 21:100
Last split date 309 Dec 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,811.99%

Management effectiveness

Return on assets (ttm)-143.52%
Return on equity (ttm)-730.48%

Income statement

Revenue (ttm)1.08M
Revenue per share (ttm)0.07
Quarterly revenue growth (yoy)66.70%
Gross profit (ttm)N/A
EBITDA -20.03M
Net income avi to common (ttm)-20.06M
Diluted EPS (ttm)-1.2300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)9.25M
Total cash per share (mrq)0.32
Total debt (mrq)1.03M
Total debt/equity (mrq)21.72%
Current ratio (mrq)1.46
Book value per share (mrq)0.17

Cash flow statement

Operating cash flow (ttm)-16.19M
Levered free cash flow (ttm)-8.26M